Welcome to our dedicated page for Citius Oncology news (Ticker: CTOR), a resource for investors and traders seeking the latest updates and insights on Citius Oncology stock.
Citius Oncology, Inc. reports developments tied to its oncology-focused biopharmaceutical business and the commercialization of LYMPHIR™ (denileukin diftitox-cxdl). The company is a majority-owned subsidiary of Citius Pharmaceuticals and develops targeted oncology therapies. LYMPHIR is FDA approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma who have received at least one prior systemic therapy.
Recurring CTOR news includes U.S. launch updates, initial revenue and operating results, institutional adoption, payer coverage, international distribution through regional partners and Named Patient Programs, and investigator-led clinical studies involving LYMPHIR in additional oncology settings. Company updates also cover medical-affairs engagement, material agreements, shareholder voting matters, capital-structure disclosures, governance matters, and clinical or regulatory disclosures.
Citius Oncology (Nasdaq: CTOR)/b), a majority-owned subsidiary of Citius Pharma (Nasdaq: CTXR), reported commercial launch metrics for (denileukin diftitox‑cxdl) for relapsed or refractory Stage I–III cutaneous T‑cell lymphoma (CTCL). As of June 30, 2026, LYMPHIR was available in 42 institutions, including academic centers, NCCN institutions and community infusion centers.
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter, while institutional vial orders from wholesalers rose 31%. According to Citius Oncology, LYMPHIR has achieved near‑universal payer coverage, and management estimates the initial U.S. CTCL market opportunity for LYMPHIR currently exceeds $400 million. LYMPHIR, launched in December 2025 following FDA approval, carries a boxed warning for capillary leak syndrome and other significant risks including visual impairment, infusion‑related reactions and hepatotoxicity, with detailed incidence rates described from pooled clinical trial data.
Citius Oncology (Nasdaq: CTOR), majority-owned by Citius Pharma (Nasdaq: CTXR), reported continued U.S. launch progress for LYMPHIR (denileukin diftitox-cxdl) for relapsed or refractory Stage I–III CTCL. The company has added 21 field-based commercial professionals and eight medical science liaisons, with nationwide deployment expected by August 2026.
According to Citius Oncology, the May 2026 financing enabled this expansion, executed with exclusive commercialization partner EVERSANA, which also supplies integrated operational services. Management cites near 100% payer coverage, expanding ordering accounts across academic and community centers, and use of a proprietary AI-driven commercial intelligence platform. LYMPHIR, FDA-approved and launched in December 2025, addresses an estimated initial CTCL market exceeding $400 million.
Citius Oncology (Nasdaq: CTOR) reported Phase 1 data from an investigator-initiated study of LYMPHIR (denileukin diftitox-cxdl) plus pembrolizumab in recurrent or refractory gynecologic malignancies presented at ASCO 2026.
Among 21 efficacy-evaluable patients, the combination achieved a 24% overall response rate, 48% clinical benefit rate, and median progression-free survival of 20.5 months in those with clinical benefit, with manageable tolerability and no new safety signals. A Phase 2 expansion is planned.
Citius Oncology (Nasdaq: CTOR) will present Phase 1 data on LYMPHIR (denileukin diftitox‑cxdl) plus pembrolizumab in relapsed/refractory gynecologic malignancies at the ASCO 2026 Annual Meeting in Chicago.
The investigator‑initiated trial reported a 24% objective response rate, average 21.1‑month duration of response in responders, and a favorable safety profile, which is described as signaling potential to augment immune checkpoint inhibitor efficacy and expand LYMPHIR’s role beyond CTCL.
The abstract (No. 2564) will be presented as a poster in the Developmental Therapeutics—Immunotherapy session on May 30, 2026, from 1:30 PM to 4:30 PM CDT.
Citius Oncology (Nasdaq: CTOR) reported fiscal Q2 2026 results and a business update. LYMPHIR® generated $1.7 million in quarterly and $5.6 million in first-half 2026 net revenue at ~80% gross margins. About 83% of target accounts have LYMPHIR on formulary or in review, with near 100% commercial payer coverage and no reimbursement denials.
The company held $2.6 million in cash at March 31, 2026, then secured up to $36.5 million in combined debt and equity in May. A one-time $19.7 million CMO contract cancellation drove G&A higher and contributed to a $26.6 million quarterly net loss.
Citius Pharmaceuticals (Nasdaq: CTXR) reported fiscal Q2 2026 results and a business update for majority-owned Citius Oncology (Nasdaq: CTOR). LYMPHIR generated $1.7M Q2 and $5.6M H1 2026 net revenue at ~80% gross margin, with payer coverage near 100% and 83% of target accounts on or in formulary review.
Citius Pharma held $4.6M cash on March 31, 2026, then raised $5M via a registered direct offering. Citius Oncology arranged up to $36.5M in combined warrant and debt financing. Management expects combined funds to support operations through November 2026. Net loss to common stockholders was $21.2M in Q2 2026, including a $19.7M one-time CMO contract cancellation charge.
The company highlighted initial LYMPHIR shipments to Europe via Uniphar, near-term completion of the U.S. commercial field force, and positive preliminary topline Phase 1 data from two investigator-initiated LYMPHIR combination studies. Engagement with the FDA continues for Mino-Lok and Halo-Lido.
Citius Oncology (Nasdaq: CTOR) secured up to $36.5 million of financing to support LYMPHIR commercialization via a up to $25 million senior secured credit facility with Avenue (initial $10 million funded) and approximately $11.5 million from immediate warrant exercises. The credit facility term is 3.5 years; warrants and certain issuances are subject to stockholder approval and registration conditions.
Proceeds will fund sales force expansion, market access, medical affairs, manufacturing support, working capital, and general corporate purposes.
Citius Oncology (Nasdaq: CTOR) announced its first shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe via a regional distribution partner on April 29, 2026, expanding patient access outside the United States.
LYMPHIR will be available through Named Patient Programs in specific countries under local regulations; it lacks EMA marketing authorization. The company continues U.S. commercial rollout after FDA approval in August 2024 and a December 2025 U.S. launch.
Citius Oncology (Nasdaq: CTOR) provided a commercial update on the U.S. launch of LYMPHIR for cutaneous T‑cell lymphoma on March 31, 2026. Early metrics show sequential order growth, 83% of target accounts progressing formulary review, ~135 health plans covering ~80% of lives, and no reported reimbursement denials. Clinical collaborations reported positive topline data at ASTCT 2026 and completed Phase I results at UPMC, with ongoing analyses and next‑stage discussions.
Commercial supply, international distribution agreements, and upcoming field team onboarding support continued launch expansion.
Citius Oncology (Nasdaq: CTOR) will attend the USCLC Annual Workshop on March 26, 2026 in Denver to discuss cutaneous T‑cell lymphoma (CTCL) care and clinical experience with LYMPHIR™ (denileukin diftitox‑cxdl), which the company recently launched in the U.S. The team will hold one‑on‑one meetings with CTCL specialists.